Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001140361-16-048509
Filing Date
2016-01-25
Accepted
2016-01-25 08:43:38
Documents
1
Period of Report
2016-01-21

Document Format Files

Seq Description Document Type Size
1 FORM 4 doc1.html 4  
1 FORM 4 doc1.xml 4 4093
  Complete submission text file 0001140361-16-048509.txt   5499
Mailing Address 343 OYSTER POINT BLVD. SUITE 100 SOUTH SAN FRANCISCO CA 94080
Business Address 343 OYSTER POINT BLVD. SUITE 100 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Issuer) CIK: 0001501989 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 343 OYSTER POINT BLVD SUITE 100 SOUTH SAN FRANCISCO CA 94080
Business Address
Goeltz II Robert C. (Reporting) CIK: 0001653881 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37587 | Film No.: 161357584